Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
KPTI - Karyopharm Therapeutics Inc.
Market Cap 204.08M P/E - EPS this Y 47.20% Ern Qtrly Grth -
Income -89.91M Forward P/E -2.01 EPS next Y -1.50% 50D Avg Chg -8.00%
Sales 145.67M PEG 0.04 EPS past 5Y - 200D Avg Chg -46.00%
Dividend N/A Price/Book N/A EPS next 5Y -30.30% 52W High Chg -70.00%
Recommedations 1.90 Quick Ratio 3.31 Shares Outstanding 124.68M 52W Low Chg 24.00%
Insider Own 6.08% ROA -31.98% Shares Float 123.03M Beta 0.19
Inst Own 56.70% ROE - Shares Shorted/Prior 17.93M/18.26M Price 1.79
Gross Margin 89.19% Profit Margin -61.73% Avg. Volume 3,435,614 Target Price 4.36
Oper. Margin -65.72% Earnings Date Oct 31 Volume 2,225,002 Change -0.56%
Healthcare | Biotechnology | United States
About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Karyopharm Therapeutics Inc. News
12/09/24 Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications
12/03/24 Karyopharm Therapeutics Provides Endometrial Cancer Program Update
12/02/24 Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/25/24 Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference
11/20/24 Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer
11/18/24 Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition
11/08/24 Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
11/06/24 Karyopharm Therapeutics Third Quarter 2024 Earnings: Beats Expectations
11/06/24 Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ...
11/05/24 Karyopharm Therapeutics (KPTI) Q3 2024 Earnings Call Transcript
11/05/24 Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates
11/05/24 Karyopharm Therapeutics: Q3 Earnings Snapshot
11/05/24 Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress
11/01/24 Earnings Preview: Amneal Pharmaceuticals (AMRX) Q3 Earnings Expected to Decline
10/31/24 Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
10/31/24 Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024
10/31/24 Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis
10/30/24 Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024
10/25/24 Highbridge Capital Management's Strategic Acquisition of Karyopharm Therapeutics Shares
09/05/24 Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics (KPTI) Looks Ripe for a Turnaround
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Paulson Richard A. President and CEO President and CEO Jan 04 Sell 0.82 4,114 3,373 783,465 01/08/24
Paulson Richard A. President and CEO President and CEO Dec 04 Sell 0.79 3,622 2,861 787,579 12/05/23
Paulson Richard A. President and CEO President and CEO Nov 06 Sell 0.9203 3,606 3,319 791,201 11/07/23
Paulson Richard A. President and CEO President and CEO Oct 04 Sell 1.27 3,589 4,558 794,807 10/05/23
BOHLIN GAREN G Director Director Sep 12 Buy 1.215 41,140 49,985 45,140 09/12/23
Paulson Richard A. President and CEO President and CEO Aug 07 Sell 1.72 3,722 6,402 802,018 08/08/23
Poulton Stuart EVP, Chief Developme.. EVP, Chief Development Officer Jul 28 Sell 1.70 2,845 4,836 156,286 08/01/23
Paulson Richard A. President and CEO President and CEO Jul 05 Sell 1.72 3,538 6,085 805,740 07/06/23
Rangwala Reshma EVP & Chief Medical.. EVP & Chief Medical Officer Apr 20 Sell 4.04 6,770 27,351 158,230 04/24/23
Paulson Richard A. President and CEO President and CEO Apr 04 Sell 3.97 3,497 13,883 816,619 04/05/23
Mason Michael EVP, CFO & Treasurer EVP, CFO & Treasurer Feb 28 Sell 3.03 11,205 33,951 245,361 03/02/23
Paulson Richard A. President and CEO President and CEO Feb 28 Sell 3.03 33,033 100,090 823,622 03/02/23
Paulson Richard A. President and CEO President and CEO Dec 05 Sell 5.17 3,490 18,043 612,527 12/06/22
Paulson Richard A. President and CEO President and CEO Nov 04 Sell 4.54 3,493 15,858 616,017 11/08/22
Paulson Richard A. President and CEO President and CEO Sep 08 Sell 5.24 3,479 18,230 622,998 09/09/22
Greene Barry E Director Director Aug 11 Option 1.485 7,576 11,250 13,606 08/15/22
Cheng Sohanya Roshan Chief Commercial Off.. Chief Commercial Officer Jun 13 Sell 5.27 1,551 8,174 89,949 06/14/22
PAKIANATHAN DEEPIKA Director Director Jun 08 Sell 6.23 538,784 3,356,624 16,673 06/10/22
Paulson Richard A. President and CEO President and CEO Jun 07 Sell 5.7602 2,542 14,642 630,906 06/08/22
Mason Michael EVP, CFO, Treasurer EVP, CFO, Treasurer Jun 03 Sell 6.05 601 3,636 138,509 06/06/22
Shacham Sharon Chief Scientific Off.. Chief Scientific Officer Feb 28 Sell 10.24 12,452 127,508 713,757 03/02/22
Kauffman Michael Director Director Feb 28 Sell 10.24 12,452 127,508 898,131 03/02/22
Kauffman Michael Director Director Feb 17 Sell 12.12 18,167 220,184 904,357 02/22/22
Shah Jatin EVP, Chief Medical O.. EVP, Chief Medical Officer Feb 07 Sell 9.862 1,704 16,805 130,756 02/09/22
Frenkel Ran EVP, Chief Dev. Offi.. EVP, Chief Dev. Officer Feb 07 Sell 9.862 1,991 19,635 104,632 02/09/22
Mason Michael EVP, CFO & Treasurer EVP, CFO & Treasurer Feb 07 Sell 9.862 3,947 38,925 53,308 02/09/22
Kauffman Michael Director Director Feb 07 Sell 9.86 13,471 132,824 913,445 02/09/22
Shacham Sharon Chief Scientific Off.. Chief Scientific Officer Feb 07 Sell 9.86 13,471 132,824 708,062 02/09/22
Shacham Sharon President & CSO President & CSO Feb 22 Sell 14.83 18,990 281,622 575,126 02/22/21
Shah Jatin EVP, Chief Medical O.. EVP, Chief Medical Officer Feb 17 Sell 15.52 1,748 27,129 48,127 02/17/21
Frenkel Ran EVP, Chief Dev. Offi.. EVP, Chief Dev. Officer Feb 17 Sell 15.52 2,046 31,754 39,338 02/17/21
Kauffman Michael Chief Executive Offi.. Chief Executive Officer Feb 17 Sell 15.52 13,243 205,531 764,147 02/17/21
Mirza Mansoor Raza Director Director Dec 22 Sell 18 5,000 90,000 12/22/20
Mirza Mansoor Raza Director Director Dec 22 Option 5.43 5,000 27,150 5,000 12/22/20
Lewis Tanya EVP,Chief Reg.&Quali.. EVP,Chief Reg.&Quality Officer Nov 04 Sell 15.58 226 3,521 539 11/04/20
Shah Jatin EVP, Chief Medical O.. EVP, Chief Medical Officer Nov 04 Sell 19.46 589 11,462 43,229 11/04/20
Primiano Christopher Brett EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary Oct 14 Option 9.8 39,271 384,856 5,370 10/14/20
Primiano Christopher Brett EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary Oct 14 Sell 17.03 39,271 668,785 4,649 10/14/20
Kauffman Michael Chief Executive Offi.. Chief Executive Officer Oct 14 Option 0.03 7,500 225 763,989 10/14/20
Kauffman Michael Chief Executive Offi.. Chief Executive Officer Oct 14 Sell 14.89 7,500 111,675 756,489 10/14/20
Shacham Sharon President & CSO President & CSO Oct 14 Option 0.03 7,500 225 763,989 10/14/20
Shacham Sharon President & CSO President & CSO Oct 14 Sell 14.89 7,500 111,675 756,489 10/14/20
Primiano Christopher Brett EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary Sep 10 Option 6.54 10,054 65,753 14,703 09/10/20
Primiano Christopher Brett EVP, CBO, GC & Secre.. EVP, CBO, GC & Secretary Sep 10 Sell 14.98 10,054 150,609 4,649 09/10/20